|
KMID : 1143420220150150940
|
|
Public Health Weekly Report
2022 Volume.15 No. 15 p.940 ~ p.950
|
|
|
Monitoring adverse events following initial vaccination with Novavax vaccine
|
|
Hwang In-Sob
Kim Hyung-Jun
Seo Sun-Young
Lee Yeon-Kyeng
Kwon Yoon-Hyung
|
|
|
Abstract
|
|
|
To investigate the incidence of adverse events following immunization (AEFIs) during the initial period of vaccination with
Novavax, which has been in use in the Republic of Korea (ROK) since February 14, 2022, monitoring based on reports of
adverse events reported by patients and guardians and active monitoring of adverse events after initial vaccination were
conducted via mobile phone text messages and phone call surveys. The status of adverse events reports after vaccination until March 12, 2022 and the incidence of adverse events symptoms were monitored for 7 days after vaccination via text messages. The results of symptom manifestation and symptom intensity using phone call surveys on the third and seventh days after vaccination are presented, and the reporting rates of adverse events after vaccination with Novavax vaccine in the ROK was clarified. The reporting rate of adverse events was 193.9 per 100,000 vaccination, which was relatively lower than that for other coronavirus disease vaccines. The reporting rates of adverse events were similar in male and female and the rate was confirmed to decrease with increasing age. Monitoring via text messages and phone calls confirmed that the type and time of occurrence of adverse events to Novavax were similar to those of other existing vaccines, and the results were not significantly different from those confirmed in clinical trials.
|
|
|
KEYWORD
|
|
|
COVID-19 vaccination, Adeverse events, Novavax vaccine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|